Contemporary management of the painful bladder: A systematic review

Antonella Giannantoni, Vittorio Bini, Roger Dmochowski, Philip Hanno, J. Curtis Nickel, Silvia Proietti, Jean Jacques Wyndaele

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Context: Different types of behavioural, dietary, interventional, pharmacologic, and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis (PBS/IC). Because of the paucity of randomised placebo-controlled studies on different treatments, an evidence-based management approach has not yet been developed. Objective: To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC, to quantify the effect size from randomised controlled trials (RCTs), and to reach clinical agreement on the efficacy of treatments for PBS/IC. Evidence acquisition: We performed a systematic review of the literature to identify articles published between 1990 and September 2010 on the management of PBS/IC. We included articles restricted to the English language published since 1990 to date that reported on oral and intravesical treatment, multimodal or combined treatment, and surgical treatment. For all RCTs, standardised mean differences (SMDs) were extracted and combined in a meta-analysis applying a random-effect model that incorporated the heterogeneity of effects. The four outcomes assessed in all studies were a change in the Interstitial Cystitis Symptom Index (ICSI), pain, urgency, and frequency. Non-RCTs (nRCTs) were analysed with a narrative synthesis of the evidence from all research designs. Evidence synthesis: We included 7709 adult patients from 29 RCTs and 57 nRCTs. Meta-analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI, pain, and frequency. Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency. The remaining RCTs showed sporadic significant changes in only one of the four considered parameters. The attributed levels of evidence for treatments reported in RCTs were 1b; grades of recommendations ranged from A to C. According to the Jadad score, 11 RCTs were high-quality studies. Meta-analysis of RCTs showed a great heterogeneity in the applied methodologies, clinical outcomes assessed, and the obtained results in different studies. The results from the nRCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing. A high heterogeneity in drugs and treatment modalities, clinical outcomes, and obtained results was also found for nRCTs. Conclusions: Limited evidence exists for the few treatments for PBS/IC. The lack of definitive conclusions is due to the great heterogeneity in methodology, symptoms assessment, duration of treatment, and follow-up in both RCTs and nRCTs.

Original languageEnglish
Pages (from-to)29-53
Number of pages25
JournalEuropean Urology
Volume61
Issue number1
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Interstitial Cystitis
Urinary Bladder
Randomized Controlled Trials
Therapeutics
Meta-Analysis
Pain
Pentosan Sulfuric Polyester
Combined Modality Therapy
Type A Botulinum Toxins
Amitriptyline
Symptom Assessment

Keywords

  • Bladder pain
  • Interstitial cystitis
  • Intravesical treatment
  • Oral treatment
  • Surgery

ASJC Scopus subject areas

  • Urology

Cite this

Giannantoni, A., Bini, V., Dmochowski, R., Hanno, P., Nickel, J. C., Proietti, S., & Wyndaele, J. J. (2012). Contemporary management of the painful bladder: A systematic review. European Urology, 61(1), 29-53. https://doi.org/10.1016/j.eururo.2011.07.069

Contemporary management of the painful bladder : A systematic review. / Giannantoni, Antonella; Bini, Vittorio; Dmochowski, Roger; Hanno, Philip; Nickel, J. Curtis; Proietti, Silvia; Wyndaele, Jean Jacques.

In: European Urology, Vol. 61, No. 1, 01.2012, p. 29-53.

Research output: Contribution to journalArticle

Giannantoni, A, Bini, V, Dmochowski, R, Hanno, P, Nickel, JC, Proietti, S & Wyndaele, JJ 2012, 'Contemporary management of the painful bladder: A systematic review', European Urology, vol. 61, no. 1, pp. 29-53. https://doi.org/10.1016/j.eururo.2011.07.069
Giannantoni A, Bini V, Dmochowski R, Hanno P, Nickel JC, Proietti S et al. Contemporary management of the painful bladder: A systematic review. European Urology. 2012 Jan;61(1):29-53. https://doi.org/10.1016/j.eururo.2011.07.069
Giannantoni, Antonella ; Bini, Vittorio ; Dmochowski, Roger ; Hanno, Philip ; Nickel, J. Curtis ; Proietti, Silvia ; Wyndaele, Jean Jacques. / Contemporary management of the painful bladder : A systematic review. In: European Urology. 2012 ; Vol. 61, No. 1. pp. 29-53.
@article{822299550a1b4c89a905919d0079611a,
title = "Contemporary management of the painful bladder: A systematic review",
abstract = "Context: Different types of behavioural, dietary, interventional, pharmacologic, and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis (PBS/IC). Because of the paucity of randomised placebo-controlled studies on different treatments, an evidence-based management approach has not yet been developed. Objective: To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC, to quantify the effect size from randomised controlled trials (RCTs), and to reach clinical agreement on the efficacy of treatments for PBS/IC. Evidence acquisition: We performed a systematic review of the literature to identify articles published between 1990 and September 2010 on the management of PBS/IC. We included articles restricted to the English language published since 1990 to date that reported on oral and intravesical treatment, multimodal or combined treatment, and surgical treatment. For all RCTs, standardised mean differences (SMDs) were extracted and combined in a meta-analysis applying a random-effect model that incorporated the heterogeneity of effects. The four outcomes assessed in all studies were a change in the Interstitial Cystitis Symptom Index (ICSI), pain, urgency, and frequency. Non-RCTs (nRCTs) were analysed with a narrative synthesis of the evidence from all research designs. Evidence synthesis: We included 7709 adult patients from 29 RCTs and 57 nRCTs. Meta-analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI, pain, and frequency. Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency. The remaining RCTs showed sporadic significant changes in only one of the four considered parameters. The attributed levels of evidence for treatments reported in RCTs were 1b; grades of recommendations ranged from A to C. According to the Jadad score, 11 RCTs were high-quality studies. Meta-analysis of RCTs showed a great heterogeneity in the applied methodologies, clinical outcomes assessed, and the obtained results in different studies. The results from the nRCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing. A high heterogeneity in drugs and treatment modalities, clinical outcomes, and obtained results was also found for nRCTs. Conclusions: Limited evidence exists for the few treatments for PBS/IC. The lack of definitive conclusions is due to the great heterogeneity in methodology, symptoms assessment, duration of treatment, and follow-up in both RCTs and nRCTs.",
keywords = "Bladder pain, Interstitial cystitis, Intravesical treatment, Oral treatment, Surgery",
author = "Antonella Giannantoni and Vittorio Bini and Roger Dmochowski and Philip Hanno and Nickel, {J. Curtis} and Silvia Proietti and Wyndaele, {Jean Jacques}",
year = "2012",
month = "1",
doi = "10.1016/j.eururo.2011.07.069",
language = "English",
volume = "61",
pages = "29--53",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier B.V.",
number = "1",

}

TY - JOUR

T1 - Contemporary management of the painful bladder

T2 - A systematic review

AU - Giannantoni, Antonella

AU - Bini, Vittorio

AU - Dmochowski, Roger

AU - Hanno, Philip

AU - Nickel, J. Curtis

AU - Proietti, Silvia

AU - Wyndaele, Jean Jacques

PY - 2012/1

Y1 - 2012/1

N2 - Context: Different types of behavioural, dietary, interventional, pharmacologic, and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis (PBS/IC). Because of the paucity of randomised placebo-controlled studies on different treatments, an evidence-based management approach has not yet been developed. Objective: To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC, to quantify the effect size from randomised controlled trials (RCTs), and to reach clinical agreement on the efficacy of treatments for PBS/IC. Evidence acquisition: We performed a systematic review of the literature to identify articles published between 1990 and September 2010 on the management of PBS/IC. We included articles restricted to the English language published since 1990 to date that reported on oral and intravesical treatment, multimodal or combined treatment, and surgical treatment. For all RCTs, standardised mean differences (SMDs) were extracted and combined in a meta-analysis applying a random-effect model that incorporated the heterogeneity of effects. The four outcomes assessed in all studies were a change in the Interstitial Cystitis Symptom Index (ICSI), pain, urgency, and frequency. Non-RCTs (nRCTs) were analysed with a narrative synthesis of the evidence from all research designs. Evidence synthesis: We included 7709 adult patients from 29 RCTs and 57 nRCTs. Meta-analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI, pain, and frequency. Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency. The remaining RCTs showed sporadic significant changes in only one of the four considered parameters. The attributed levels of evidence for treatments reported in RCTs were 1b; grades of recommendations ranged from A to C. According to the Jadad score, 11 RCTs were high-quality studies. Meta-analysis of RCTs showed a great heterogeneity in the applied methodologies, clinical outcomes assessed, and the obtained results in different studies. The results from the nRCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing. A high heterogeneity in drugs and treatment modalities, clinical outcomes, and obtained results was also found for nRCTs. Conclusions: Limited evidence exists for the few treatments for PBS/IC. The lack of definitive conclusions is due to the great heterogeneity in methodology, symptoms assessment, duration of treatment, and follow-up in both RCTs and nRCTs.

AB - Context: Different types of behavioural, dietary, interventional, pharmacologic, and surgical therapies have been used to treat painful bladder syndrome/interstitial cystitis (PBS/IC). Because of the paucity of randomised placebo-controlled studies on different treatments, an evidence-based management approach has not yet been developed. Objective: To critically review and synthesize data from a wide range of current therapeutic approaches to PBS/IC, to quantify the effect size from randomised controlled trials (RCTs), and to reach clinical agreement on the efficacy of treatments for PBS/IC. Evidence acquisition: We performed a systematic review of the literature to identify articles published between 1990 and September 2010 on the management of PBS/IC. We included articles restricted to the English language published since 1990 to date that reported on oral and intravesical treatment, multimodal or combined treatment, and surgical treatment. For all RCTs, standardised mean differences (SMDs) were extracted and combined in a meta-analysis applying a random-effect model that incorporated the heterogeneity of effects. The four outcomes assessed in all studies were a change in the Interstitial Cystitis Symptom Index (ICSI), pain, urgency, and frequency. Non-RCTs (nRCTs) were analysed with a narrative synthesis of the evidence from all research designs. Evidence synthesis: We included 7709 adult patients from 29 RCTs and 57 nRCTs. Meta-analysis of RCTs showed that only cyclosporine A provided a simultaneous great effect size of SMD on ICSI, pain, and frequency. Amitriptyline at different dosages showed a great effect size of SMD on pain and urgency or on ICSI and frequency. The remaining RCTs showed sporadic significant changes in only one of the four considered parameters. The attributed levels of evidence for treatments reported in RCTs were 1b; grades of recommendations ranged from A to C. According to the Jadad score, 11 RCTs were high-quality studies. Meta-analysis of RCTs showed a great heterogeneity in the applied methodologies, clinical outcomes assessed, and the obtained results in different studies. The results from the nRCTs showed that the most frequently adopted treatment is oral pentosan polysulfate and that the use of botulinum A toxin intradetrusorial injections in PBS/IC is increasing. A high heterogeneity in drugs and treatment modalities, clinical outcomes, and obtained results was also found for nRCTs. Conclusions: Limited evidence exists for the few treatments for PBS/IC. The lack of definitive conclusions is due to the great heterogeneity in methodology, symptoms assessment, duration of treatment, and follow-up in both RCTs and nRCTs.

KW - Bladder pain

KW - Interstitial cystitis

KW - Intravesical treatment

KW - Oral treatment

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=82255174934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82255174934&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2011.07.069

DO - 10.1016/j.eururo.2011.07.069

M3 - Article

C2 - 21920661

AN - SCOPUS:82255174934

VL - 61

SP - 29

EP - 53

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -